Search
rsPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnThe vaccine comprises purified rsPSMA protein formulated with Alhydrogel® adjuvant. … entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003).
Bucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]
Pentastarch
go.drugbank.com/drugs/DB09111ApprovedWithdrawnIt is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. … When administered, pentastarch remains mainly in the circulatory system and hence, it is considered a plasma expander.
Xamoterol
go.drugbank.com/drugs/DB13781ApprovedIt modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors. … Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients.
Bevantolol
go.drugbank.com/drugs/DB01295InvestigationalBevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. … Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
Dexamethasone acetate
go.drugbank.com/drugs/DB14649ApprovedInvestigationalVet approvedCommonly known as decadron, dexamethasone acetate is a glucocorticosteroid previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and other conditions. … [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions.
Prenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalIt is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Oxantel
go.drugbank.com/drugs/DB13670InvestigationalOxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.
Mixtures: PAMOATO DE PIRANTEL/PAMOATO DE OXANTEL SUSPENSION, PAMOATO DE OXANTEL 250 MG/5ML + PAMOATO DE PIRANTEL 250 MG/5 ML SUSPENSIÓN.